Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
12.4M
-
Number of holders
-
99
-
Total 13F shares, excl. options
-
7.66M
-
Shares change
-
+7.66M
-
Total reported value, excl. options
-
$198M
-
Value change
-
+$198M
-
Put/Call ratio
-
1.28
-
Number of buys
-
97
-
Price
-
$25.84
Significant Holders of NEKTAR THERAPEUTICS - Common Stock, $0.0001 par value (NKTR) as of Q2 2025
109 filings reported holding NKTR - NEKTAR THERAPEUTICS - Common Stock, $0.0001 par value as of Q2 2025.
NEKTAR THERAPEUTICS - Common Stock, $0.0001 par value (NKTR) has 99 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7.66M shares
of 12.4M outstanding shares and own 61.71% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (729K shares), Nantahala Capital Management, LLC (710K shares), MILLENNIUM MANAGEMENT LLC (649K shares), AQR CAPITAL MANAGEMENT LLC (428K shares), ACADIAN ASSET MANAGEMENT LLC (421K shares), BlackRock, Inc. (415K shares), Balyasny Asset Management L.P. (386K shares), PRIMECAP MANAGEMENT CO/CA/ (300K shares), TCG Crossover Management, LLC (267K shares), and RENAISSANCE TECHNOLOGIES LLC (247K shares).
This table shows the top 99 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.